The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 238 participants.

Also called NCT02433119

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 238 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02433119
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02433119. Randomized; quadruple masking; primary purpose treatment. Start 2015-03-16 (actual); primary completion 2016-09-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
Condition
Hypertension
Intervention (Drug)
OROSARTAN® 5/160mg
Intervention (Drug)
CODIOVAN® 160/12.5mg
Lead sponsor
Dong-A ST Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02433119
Content hash
68c1faac552809b7c60fb0a8a12b4f76fe9b9963bfe1de5d15e88161f0c44188